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CortisolExercise intolerance, as evidenced by a worsening of pain, fatigue, and stiffness after novel exertion, is a key
feature of ﬁbromyalgia (FM). In this pilot study, we investigate whether; insufﬁcient muscle repair processes
and impaired anti-inﬂammatory mechanisms result in an exaggerated pro-inﬂammatory cytokine response to
exhaustive exercise, and consequently a worsening of muscle pain, stiffness and fatigue in the days post-
exercise.Wemeasured changes inmuscle pain and tenderness, fatigue, stiffness, and serum levels of neuroendo-
crine and inﬂammatory cytokine markers in 20 women with FM and 16 healthy controls (HCs) before and after
exhaustive treadmill exercise. Compared to HCs, FM participants failed tomount the expected anti-inﬂammatory
response to exercise and experienced a worsening of symptoms post-exercise. However, changes in post-
exertional symptomswere not mediated by post-exertional changes in pro-inﬂammatory cytokine levels. Impli-
cations of these ﬁndings are discussed.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Fibromyalgia (FM) is a chronic and often debilitating disorder
characterized by widespread pain; other symptoms commonly include
tenderness, stiffness, fatigue, sleep, mood disturbances and reports of
worsening symptoms following novel exertion. FM affects an estimated
11 million persons in the United States, 80–90% of whom are women
(Queiroz, 2013). FM patients are typically sedentary and overweight
or obese (Yunus et al., 2002) with physical inactivity contributing to
an increased risk formetabolic related co-morbidities in this population
(Loevinger et al., 2007). Regular exercise is a key component of most
comprehensive FM-management programs (Busch et al., 2013). Of the
N120 exercise interventions in FM, most have failed tomeet the current
exercise recommendation for health by The American College of Sports
Medicine (ACSM) and the American Heart Association (AHA) guide-
lines. These organizations recommend moderate to vigorous intensitytitute of Health Professions, 36
ates. Tel.: +1 617 724 3454.
Ojerio),
.edu (N.F. Dieckmann),
u (R.M. Bennett),
.edu (A.J. Guarino),
. This is an open access article underexercise to prevent adverse health outcomes related to sedentary life-
styles (Nelson et al., 2007; Garber et al., 2011; Busch et al., 2013).
Prior exercise studies modiﬁed for FM suggest that individuals who
can tolerate the intervention can improve aerobic capacity, muscle
strength, balance and ﬂexibility and attain some symptom relief, par-
ticularly decreased pain, tenderness, fatigue, and stiffness (Busch et al.,
2013). Yet FM patients often reported several days of increased pain
and tenderness following moderate to high-intensity exercise, which
may explain why many of these prior exercise interventions suffered
from high attrition rates and inconsistent effect sizes (Jones et al.,
2006). FM represents an important clinical population that would ben-
eﬁt from establishing speciﬁc exercise guidelines that would maximize
beneﬁts while minimizing post-exertional symptom exacerbation. Un-
derstanding the molecular mechanisms underlying FM symptom exac-
erbation following moderate to high-intensity exercise may help to
guide the development of exercise guidelines in FM. The overall hypoth-
esis guiding the present study is that increased post-exertional symp-
tom exacerbation in FM is related to an abnormal neuroendocrine and
immune system response to moderate to high-intensity exercise. Con-
sistent with this hypothesis are reports of a blunted GH response to
high-intensity exercise and lower resting levels of its primary down-
stream effecter, insulin-like growth factor 1 (IGF-1), in people with
FM (Paiva et al., 2002; Ross et al., 2010; Bote et al., 2012). GH is justthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ACTH, cortisol, IL-6, IL-10, and IL-1RA that are up-regulated during
exercise (Walsh et al., 2011). The exercise-induced inﬂammatory
cytokine response was originally attributed to muscle microtrauma
(Bruunsgaard et al., 1997), which can occur during high-intensity
exercise or unnacustomed exercise in a deconditioned individual.
Muscle microtrauma triggers the localized production of the pro-
inﬂammatory cytokines IL-1β andTNF-αwhichpromote the inﬁltration
of immune cells into the damaged area. These inﬁltrating immune cells
secrete IL-1β, TNF-α and other inﬂammatory molecules including IL-6,
IL-8, IL-1RA and IL-10 (Nieman et al., 2006a, 2006b). The ability of IL-
1β and TNF-α to stimulate muscle nociceptors likely explains the char-
acteristic pain and tenderness following muscle damaging exercise
(Borghi et al., 2014a, 2014b). In addition IL-1β and TNF-α play a central
role in the development of sickness behavior, the predominant symp-
tom of which is fatigue (Dantzer, 2009). However, it has since been
shown that exercise-induced increases in circulating IL-6, IL-10, and
IL-1RA can occur in the absence ofmusclemicrotrauma, and in this con-
text their production is not preceded by IL-1β or TNF-α (Welc and
Clanton, 2013). Further studies revealed that the predominant source
of IL-6 released during non-muscle damaging exercise is exercising
muscle cells which led to the classiﬁcation of IL-6 as a “myokine”
(Pedersen and Febbraio, 2012). Exercise-induced increases in circulat-
ing ACTH, GH, cortisol, IL-10, and IL-1RA can be attributed to muscle-
derived IL-6 (Traustadottir et al., 2004; Walsh et al., 2011; Bote et al.,
2012). By stimulating the production of anti-inﬂammatory molecules
such as cortisol, IL-1RA, and IL-10, muscle-derived IL-6 has a net anti-
inﬂammatory effect and elevated IL-6 either from infusion or exercise
can decrease TNF-α levels in both rodents and humans (Starkie et al.,
2003; Petersen and Pedersen, 2005; Ploeger et al., 2009). GH regulates
the synthesis of IGF-1 which plays an important role in controlling
the pro-inﬂammatory cytokine response to muscle microtrauma and
coordinating the repair processes thereafter (Matheny et al., 2010).
Taken together, we concluded that insufﬁcient muscle repair processes
(GH/IGF-1 axis defect) and impaired anti-inﬂammatory mechanisms
(blunted cortisol, IL-10 and IL-1RA) in FMwould result in an exaggerat-
ed pro-inﬂammatory cytokine response (elevated IL-1β, TNF-α, IL-6,
and IL-8) to unaccustomed exercise and consequently a worsening of
muscle pain, stiffness and fatigue in the days post-exercise. The purpose
of the present study was to generate preliminary evidence to support
this hypothesis.
2. Methods and procedures
2.1. Inclusion and exclusion criteria
The target FM population was women less than 60 years of age,
diagnosed with FM by 1990 ACR criteria for at least two years, who
had experienced FM symptoms ≥6 years, and were willing to undergo
the testing protocol. The upper age cut-off was chosen to reduce the risk
of adverse cardiac event during treadmill stress testing. Healthy controls
(HCs) were women pair matched to FM patients (see below). Exclusion
criteria for both groups were; 1) regular participation in aerobic or
strength programs for more than 30 min three times a week, 2) preg-
nant or nursing, 3) major depressive disorder, 4) daily use of opioids,
5) current or past malignancy, 6) major organ disease or autoim-
mune/inﬂammatory disease, 7) elective surgery 30 days prior or
during the 12 day study, and 8) involvement in disability litigation
hearings. Participants were requested not to change medications
or non-pharmacologics (e.g., exercise, physical therapy) during the
course of the 12-day study.
2.2. Procedure for participant recruitment
A database of conﬁrmed FM patients managed by the Fibromyalgia
Information Foundation was used for subject recruitment. Field codesidentiﬁed zip code, age and sex for inclusion/exclusion criteria and
demographics. E-Blasts were sent to 344 potential subjects. Of those,
86 candidates completed an online interest form and were called for a
telephone screening by research staff. At that point, the potential sub-
jects were asked to conﬁrm further inclusion/exclusion criteria and
then scheduled for a study appointment. The HC participants were re-
cruited using an interested person database repository of previous re-
search participants who gave consent to be re-contacted for other
research opportunities, and in addition, participants were recruited by
posting a local craigslist ad in the Portland Metro area. Eligibility of in-
terested personswas assessed by phone. Interested and eligible HC par-
ticipantswere then evaluated based on age, estimated BMI to determine
whether they may be a potential ‘match’ for an FM patient enrolled in
the study. In total, 87 interested women responded to recruitment ma-
terial as HCs and of those, 17were eligible and conﬁrmedmatches. Once
a match was conﬁrmed, the HC participant was scheduled for the study
testing procedures. One HC participant was unable to complete the
treadmill testing due to an acute illness during the 12-day protocol, so
16 women completed the entire protocol as HC matches. FM and HCs
were females matched ton age (±5 years), percentage of body fat
(±15%), and menopausal status. There were 4 FM patients that were
included in the present analysis for which no matched control could
be identiﬁed.
2.3. Procedure overview
Eligible participants underwent four study visits during 12-days of
data collection. At Visit 1 (Day 1), written informed consentwas obtain-
ed and participants underwent a manual tender-point assessment and
completed the Revised Beck Depression Inventory (BDI-R) question-
naire to conﬁrm eligibility. Each participant then underwent pressure
pain threshold (PPT) testing and body composition testing by DEXA to
measure the percentage of body fat. Visit 2 occurred between 8 and
11:00 am 7-days after Visit 1 with fasting treadmill exercise to VO2
peak using the modiﬁed Balke protocol (ACSM Guidelines). The modi-
ﬁed Balke protocol was chosen for this study because the incremental
increase in exercise intensity is gradual but still allows for the accurate
assessment of V02 peak in FM patients. In addition, this protocol has
been used previously to examine the GH response to exhaustive
exercise (Paiva et al., 2002; Jones et al., 2007). Upon arrival at the CTU
participants had an indwelling intravenous catheter placed in their
forearms by a study nurse 1 h prior to the treadmill test. During
this hour, participants completed study surveys. Blood was collected
through the catheter three times during the treadmill test; immediately
before exercise, at peak exercise (VO2 peak), and then 60-minutes after
peak exercise. All participants returned 2- and 4-days after the treadmill
test for repeat PPT assessments and peripheral blood draws, and com-
pletion of the FIQR/SIQR (Day 4 post-exercise only). The study protocol
was approved by the University's Institutional Review Board.
2.3.1. Demographic data
Demographic data was obtained using an investigator-designed
questionnaire (disability, menopausal status and hormone replacement
therapy in women, medications, and duration of FM).
2.3.2. Revised Fibromyalgia Impact Questionnaire (FIQR) and the Revised
Symptom Impact Questionnaire (SIQR)
Participants completed the FIQR or SIQR at the beginning and end of
the study period. The FIQR is a self-report 21-item instrument that as-
sesses symptoms during the past week using a 0 to 10 scale (Bennett
et al., 2009). The FIQR has three domains: physical function, overall ef-
fect of FM, and FM symptoms (pain, fatigue, un-refreshing sleep, stiff-
ness, anxiety, depression, tenderness to touch, memory, balance and
environmental sensitivity). The SIQR is the same as the FIQR except
the word ﬁbromyalgia is replaced with “symptom.” The SIQR is used
to assess symptomatology in non-ﬁbromyalgia patients (Friend and
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present study.
2.3.3. Revised Beck Depression Inventory (BDI-R)
The BDI-R was used to screen for major depression since depres-
sion is hypothesized to alter the neuroendocrine and inﬂammatory
axes (Pariante and Lightman, 2008; Dantzer, 2012). The BDI-R
is the standard, 21-item BDI scale for assessment of depressive
symptoms and behaviors which has been adapted for use with FM
patients. This adaptation has better accuracy, sensitivity, and speci-
ﬁcity in an FM population than the original instrument (Burckhardt
et al., 1994).
2.3.4. The Manual Tenderpoint Survey (MTPS)
Overall tender point tenderness was performed at the beginning
of the study period. FM patients rated their pain level during digital
palpation of each of 18 tender points on a 0 to 10 scale with 0
meaning no pain and 10 meaning worst pain. A pain rating of 2
was required to count a tender point as positive. The Fibromyalgia
Tender Point Score (FTPS) was determined by averaging the 18 ten-
der point scores.
2.3.5. Anthropometrics
A stadiometer was used to measure height to the nearest 0.1 cm.
Weight was measured to the nearest 0.1 kg (with shoes, socks and
headgear removed) using a single pair of electronic scales. BMI (weight
in kg/height inm2)was calculated.Whole body fatmass and percentage
of whole body fat were obtained by whole body dual energy X-ray
absorptiometry (DXA) (Hologic QDR Discovery Densitometer,
Hologic, Inc., Bedford, MA; software version 12.0). DXA scans were
performed by a licensed technician who was responsible for proper
positioning, scan protocol, and scan analysis. Participants wore min-
imal clothing and were scanned in the supine position. The percent-
age of whole body fat (%Whole Body Fat = 100 − (%Whole Body
Lean Mass + %Whole Body Bone Mineral Content)) was calculat-
ed/was obtained and used to pair match FM and HC within ±15%
of Whole Body Fat Mass. Hip and waist circumference were mea-
sured and hip to waist ratio calculated.
2.3.6. Pressure algometry
The pain pressure threshold (PPT) was assessed over the lower, mid,
and upper anterior thigh and the nail bed of the thumb before the start
of the study and then 2- and 4-days after the exercise test. PPT was
measured using a Fisher's hand held dolorimeter. Pressure at a rate of
approximately 1 kg/cm2 per second was applied until the subject indi-
cated that the sensation changed from pressure to pain. The PPT for
each test site and both legs were summed.
2.3.7. Fasting treadmill exercise to VO2 peak
Participants completed the modiﬁed Balke treadmill test after
fasting for 12-hours (water allowed) and abstaining from all pain med-
ications on themorning of the treadmill testing. All treadmill tests were
performed between 8 am and 11 am. Participants were ﬁtted with 12
ECG electrodes and a Hans-Rudolph respiratory exchange mask. They
were asked to walk on a treadmill (SMC2000) using the modiﬁed
Balke protocol for VO2 peak testing (Burckhardt et al., 1989). Brieﬂy,
treadmill speed was set at 2.0 mph; 0% grade for 3 min, then elevation
increase of 2.5% every 3 min until a 17.5% grade was achieved and then
speed increased to 3.0 mph; 12.5% grade for 3 min, then elevation in-
crease of 2.5% every 3 min until 20% grade. Respiratory gas exchange
was measured using a metabolic cart (Sensor Medics VMAX 29). Contin-
uous monitoring of ECG, pulse rate, and blood pressure was performed
using a Sensor Medics Cardiosoft ECTG system. The maximal treadmill
exercise test was deﬁnedwhen either of 2 goals weremet: 1) respiratory
exchange ratio (RER) N1.1 for 30 consecutive seconds, or 2) exhaustion
scale (Borg) value of 10 (maximumperceived effort). Theneuroendocrineand inﬂammatory responses to exercise are dependent upon how
vigorous the exercise is and its duration. Thus, work performed by
each participant was calculated using the following equation: peak
workload = (distance/time) ×treadmill grade × weight. Relative VO2
peak (mL/Kg/min) was used as a measure of physical ﬁtness and time
spent on the treadmill was used as a measure of physical endurance.
2.3.8. Blood collection and measurement of neuroendocrine and
inﬂammatory serum markers
During the treadmill test, 10 mL of peripheral blood was collected
from a peripheral intravenous lock at 1) pre-exercise, 2) peak-exercise
(VO2 peak), and 3) 60-minute post-peak exercise. Following the tread-
mill test, the participant refrained from eating until after the 3rd blood
draw (1-hour post-exercise) because hyperglycemia can dampen the
GH response to exercise. Blood was allowed clotting for 4-hours at
room temperature before centrifugation at 2000 ×g for 20 min at
room temperature. Serum was removed, aliquoted then immediately
stored at−87 °C before analysis. Samples were frozen and thawed no
more than twice prior to analysis. Serum GH, ACTH, IL-1β, IL-6, IL-8,
IL-10, IL-1RA, and TNF-αweremeasured using bead-based immunoﬂu-
orescence assays commercially available from Millipore Inc. Assays
were run in triplicate according to the manufacturers' protocol. A ﬁve-
parameter regression formula was used to calculate the sample concen-
trations from the standard curves. Data were collected and analyzed
using the Luminex-100 system Version IS (Luminex, Austin, TX).
Serum cortisol was measured in duplicate by a chemiluminescent im-
munoassay using the automated immulite system (Siemens Healthcare
Diagnostics, Tarrytown,NY 10591). This assay has an analytical sensitiv-
ity of 0.2 μg/dL and the average percent difference between duplicates
was 5.5%.
2.4. Analysis
Serum analyte data were not normally distributed, and so data were
subjected to logarithmic transformation (Ln) before all statistical analy-
ses. Oneway ANOVAwas used to test for differences in continuous var-
iables at baseline, and the χ2 test was used for categorical variables. A
two (FM vs. HC) × 3 (pre-, peak-, and post-exercise) repeated measure
ANOVA was used to analyze differences in exercise-induced changes in
serumneuroendocrine and inﬂammatory analytes and PPT between FM
andHCs. Both linear and quadratic contrasts were tested on the time ef-
fect. Mauchley's test was used to test for sphericity and if violated tests
with adjusted df were used (Greenhouse–Geisser). Change in fatigue
and stiffness was calculated from pre- and post-exercise FIQR and
SIQR scores. All data are presented as mean ± standard error of the
mean (SEM). Primary analyses were conducted with the R statistical
software package (R Core Team, 2014). Exploratory mediation analyses
were performed using Mplus statistical software, which allows the di-
rect estimation of mediating (indirect) effects. Mediation models were
only tested for serum neuroendocrine and inﬂammatory analytes and
symptom outcomes that were signiﬁcantly different across patient
group (FM versus HCs).
3. Results
3.1. Demographics
Demographic data is shown in Table 1. The total sample was
Caucasian (91.7%), non-Hispanic (94.4%), in a committed relation-
ship (72.2%), employed (50% working at least part-time outside of the
home) and receiving income (77.8% earning less than $99,999/year).
There were no differences between the two groups in ethnicity,
race, marital status, employment, income level, menopausal status,
or estrogen status. There was a near signiﬁcant group difference in
education; 75% of HCs were college graduates compared to only
40% of women in the FM group.
Table 1
Demographic characteristics of sample.
Variable Group
Controls
(n = 16)
FM
(n = 20)
χ2 p
Ethnicity 1.694 .193
□ Hispanic or Latino 0 (0.0) 2 (10.0)
□ Not Hispanic or Latino 16 (100.0) 18 (90.0)
Race .839 .657
□ Caucasian or White 15 (93.8) 18 (90.0)
□ Black or African American 0 (0.0) 0 (0.0)
□ Asian 0 (0.0) 0 (0.0)
□ American Indian or Alaskan Native 0 (0.0) 1 (5.0)
□ Native □ Hawaiian or Paciﬁc
Islander
0 (0.0) 0 (0.0)
□ Other 1 (6.3) 1 (5.0)
Marital status .173 .677
□ In a committed relationship 11 (68.8) 15 (75.0)
□ Not in a committed relationship 5 (31.3) 5 (25.0)
Education 5.760 .056
□ Some high school or GED GEDan
school/graduate/GED
2 (12.5) 2 (10.0)
□ Some college/trade school graduate 2 (12.5) 10 (50.0)
□ College graduate 12 (75.0) 8 (40.0)
Income 1.527 .676
□ Under $25,000 5 (31.3) 3 (15.0)
□ $25,000–49,999 2 (12.3) 4 (20.0)
□ $50,000–99,999 6 (37.5) 8 (40.0)
□ $100,000–199,999 3 (18.8) 5 (25.0)
Employment 4.294 .231
□ Full time 4 (25.0) 4 (20.0)
□ Part Time 6 (37.5) 4 (20.0)
□ Not employed/homemaker 6 (37.5) 8 (40.0)
□ Disabled 0 (0.0) 4 (20.0)
Menopausal status .747 .688
□ Post-menopausal 10 (62.5) 12 (60.0)
□ Post-menopausal taking HRT 1 (6.3) 3 (15.0)
□ Pre-menopausal 5 (31.2) 5 (25.0)
Estrogen status .023 .878
□ Positive 6 (37.5) 8 (40.0)
□ Negative 10 (62.5) 12 (60.0)
Values in parentheses represent the percentage of participants in each category. HRT is
hormone replacement therapy, post-menopausal is no menses for≥12 months, estrogen
positive is premenopausal or post-menopausal taking HRT, χ2 is Pearson's Chi Square.
Table 2
Baseline characteristics of sample SEM is the standard error of themean. BDI-R is the Beck
Depression Inventory-Revised. FIQR is the Revised Fibromyalgia Impact Questionnaire.
SIQR is the Revised Symptom Impact Questionnaire. VAS = Visual Analogue Scale.
Variable Group One way
ANOVA
Control
(n = 16)
FM (n = 20) F p
Mean ± SEM Mean ± SEM
Age (years) 52.2 ± 1.5 52.0 ± 1.4 .005 .942
Percent body fat 38.6 ± 1.4 41.8 ± 2.1 1.470 .234
Hip to waist ratio 1.2 ± 0.03 1.2 ± 0.02 1.494 .230
Depression (BDI-R) 4.0 ± 1.1 6.2 ± 1.2 1.937 .174
Years with FM symptoms – 23.0 ± 1.0 – –
Tender point ratings 1.6 ± 0.3 7.4 ± 0.4 128.3 b .001
Pain pressure threshold
(PPT)
10.0 ± 0.5 5.2 ± 0.4 52.789 b .001
FIQR/SIQR
□ Pain VAS 0.5 ± 0.2 6.0 ± 0.5 108.836 b .001
□ Fatigue VAS 0.9 ± 0.2 5.7 ± 0.5 70.586 b .001
□ Stiffness VAS 1.0 ± 0.3 5.8 ± 0.6 44.295 b .001
□ Total FIQR/SIQR 3.9 ± 0.7 45.0 ± 4.6 61.719 b .001
SEM is standard error of themean. BDI-R is the BeckDepression Inventory-Revised. FIQR is
the Revised Fibromyalgia Impact Questionnaire. SIQR is the Revised Symptom Impact
Questionnaire. VAS = Visual Analogue Scale.
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Baseline characteristics of the FMand control participants are shown
in Table 2. There were no signiﬁcant group differences in age, percent-
age of body fat, or hip to waist ratio. None of the participants met the
criteria for major clinical depression based on scores from the BDI-R.
There was no signiﬁcant difference between FM and HCs in total
BDI-R score. Consistent with the ACR criteria for the classiﬁcation of
FM, FM patients had higher tender point ratings than HCs. None of the
HCs met the 1990 ACR diagnostic criteria for FM. FM participants had
higher levels of muscle tenderness in the quadriceps muscles on PPT
testing compared to HCs. As expected levels of bodily pain, fatigue and
stiffness levels, based on the FIQR/SIQR results,were signiﬁcantly higher
in FM subjects than HCs.
3.3. Neuroendocrine and inﬂammatory cytokine response to exercise
All participants completed the Modiﬁed Balke treadmill protocol to
volitional exhaustion (Table 3). Seventy ﬁve percent of controls and
65% of FM participants ending the test by reaching a 10 on the 1–10
BORG Rating of Perceived Exertion scale, and 25% of controls and 35%
of FM patients reached an RER N1.1 to deﬁne their VO2 peak. There
were no differences in the reason for ending exercise, physical ﬁtness,
physical endurance workload RER resting heart rate (HR) or maximum
HR.
3.3.1. Neuroendocrine response during exercise
Fig. 1 shows plots of serum ACTH, GH, and cortisol levels collected
pre-, peak-, and post-exercise. We observed a signiﬁcant quadratic
group by time interaction accounting for 13% of the variance of ACTH
levels across time (F(1,34) = 5.05, p = .03, ηp = .13). ACTH levels
increased in HCs during exercise, peaked at the end of exercise and
returned to baseline thereafter. This ACTH response was absent in FM
participants. Although a similar quadratic pattern was observed for
serum GH levels, there was not a signiﬁcant difference between the
FM or HC groups (F(1,32) = .04, p = .84). A near signiﬁcant linear
time by group interaction accounted for 10% of the variance in cortisol
levels across time (F(1,34) = 3.95, p = .06, ηp = .10).
3.3.2. Inﬂammatory cytokine response during and after exercise
Fig. 2 shows plots of serum IL-6, IL-10, TNF-α, and IL-8 levels during
the exercise test and 2- and 4-days thereafter. Levels of IL-1β and IL-1RA
were below the threshold of detection in greater than 60% of samples
screened and therefore these data are not shown. There was signiﬁcant
linear group by time interaction accounting for 12% of the variance in IL-
6 levels across time (F(1,34) = 4.57, p = .04, ηp = .12). There was also
a signiﬁcant quadratic group by time interaction accounting for 21% of
the variance in IL-10 levels across time (F(1,34) = 9.08, p = .005,
ηp = .21). While IL-6 increased in both FM and HCs during the exercise
test, post-exercise levels fell more rapidly in the HCs than in the FM
group. The difference between HCs and FMs in the pattern of changeTable 3
Performance on the modiﬁed Balke Treadmill test.
Variable Group ANOVA
Control
(n = 16)
FM (n = 20) F p
Physical ﬁtness (relative VO2 peak)
(mL/kg/min)
30.9 ± 1.3 28.2 ± 1.9 1.229 .275
Physical endurance (minutes on
treadmill)
20.4 ± 1.2 18.4 ± 1.4 .855 .362
Workload (watts) 140 ± 8.8 135 ± 8.0 .245 .642
RER at VO2 peak 1.001 ± 0.02 1.003 ± 0.02 .004 .952
Resting heart rate (beats/minute) 81 ± 2.3 80 ± 3.8 .010 .920
Maximum heart rate (beats/minute) 167 ± 3.8 157 ± 4.5 2.981 .093
Values are the mean ± SEM.
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Fig. 1.Neuroendocrine response during exercise. Serum levels of ACTH,GH, and cortisol in FM (open circle) andHCs (closed square) collected at pre-exercise (Pre), at VO2 peak (Peak), and
1-hour after VO2 peak (Post). Each data point represents themean± SEM. Serum analyte datawere not normally distributed and so datawas subjected to logarithmic transformation (Ln)
before all statistical analyses. A two (FM vs. HC) × 3 (pre-, peak-, and post-exercise) repeated measure ANOVA was used to analyze differences in exercise-induced changes in serum
neuroendocrine and inﬂammatory analytes and PPT between FM and HCs. Both linear and quadratic contrasts were tested on the time effect.
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during exercise this responsewas blunted in the FM group. For TNF-α, a
signiﬁcant linear groupby time interaction accounted for 30% of the var-
iance in the levels across time (F(1,34) = 14.34, p = .001, ηp = .30).
Whereas exercise decreased serum TNF-α in HCs, it had a very small
stimulatory effect on TNF-α level in the FM group. There was also a sig-
niﬁcant linear group by time interaction accounting for 12% of the vari-
ance in IL-8 levels across time (F(1,34) = 4.51, p = .04, ηp = .12). A0.0
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Fig. 2. Inﬂammatory cytokine response during and after exercise. Serum levels of IL-6, IL-10, TN
VO2 peak (peak), 1-hour after VO2 peak (Post), 2-days after exercise (Day 2), and 4-days after e
normally distributed and so datawas subjected to logarithmic transformation (Ln) before all sta
was used to analyze differences in exercise-induced changes during exercise, and a 2 (FM vs. HC
post-exertional changes in each inﬂammatory analyte.sharper decline in serum IL-8 levels in the 60min post-exercise was ob-
served in the HCs compared to the FM group.
We then examined changes in IL-6, IL-10, TNF-α, and IL-8 between
the HC and FM groups from pre-exercise to— and 4-days after exercise.
Therewere no signiﬁcant group by time interactions for IL-6 (F(2,68)=
.86, p = .43), or IL-10 (F(1,68) = 1.53, p = .22) or TNF-α levels across
time (F(2,68) = 1.28, p = .29). We did observe a signiﬁcant quadratic
group by time interaction accounting for 21% of the variance in IL-80.5
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F-α, and IL-8 in FM (open circle) andHCs (closed square) collected at pre-exercise (pre), at
xercise (Day 4). Each data point represents themean± SEM. Serum analyte data were not
tistical analyses. A 2 (FMvs. HC)× 3 (pre-, peak-, and post-) and repeatedmeasure ANOVA
)× 3 (pre-, Day 2, and Day 4) repeatedmeasure ANOVAwas used to analyze differences in
165B. Torgrimson-Ojerio et al. / Journal of Neuroimmunology 277 (2014) 160–167scores across time (F(1,34) = 8.84, p = .005, ηp = .21). In HCs, IL-8
levels at 2- and 4-days post-exercisewere similar to pre-exercise levels,
whereas they decreased in FM participants.
3.4. Post-exertional pain, tenderness, fatigue and stiffness
Change in local pain and tenderness in the upper thigh muscles was
assessed using the PPT test at baseline, then 2 days and 4 days post-
exercise. There was a signiﬁcant linear group × time interaction that
accounted for 27% of the variance in PPT scores across time. FM patients
experienced lower thresholds for pain and greater local tenderness
whereas controls experienced higher thresholds for pain and less local
tenderness following the exercise test (F(1,33) = 6.24, p = .001,
ηp = .27; Fig. 3A). In contrast, exercise had no group effect on change
in pain and tenderness of the thumb, the control site (p= .463). Change
in fatigue and stiffnesswas calculated frompre- and post-exercise FIQR/
SIQR scores. FM participants reported signiﬁcantly greater changes in
fatigue (1.3 ± 0.4 vs. 0.2 ± 0.1, F(1,34) = 7.81, p = .008, ηp = .19)
and stiffness than HCs (0.5 ± 0.4 vs.−0.6 ± 0.3, F(1,34) = 4.94, p =
.033, ηp = .213, Fig. 3B).
3.5. Meditation effects
Exploratorymediation analyses were performed to examinewheth-
er the neuroendocrine (ACTH or cortisol) or inﬂammatory cytokine
(IL-6, IL-8, IL-10 or TNF-α) response to exercise mediated changes
in post-exertional symptoms.We found no signiﬁcantmediation effects
between group (FM or HC), exercise-induced changes in serum neu-
roendocrine and inﬂammatory analytes (mediators), and exercise-
induced changes in symptoms (muscle pain, fatigue, or stiffness).
Implications of these ﬁndings are discussed below.
4. Discussion
Prior exercise interventions in FM have documented a worsening of
symptoms in FM following high-intensity exercise. The purpose of the
present study was to explore one potential mechanism underlying post-
exertional symptoms in FM. Speciﬁcally, we sought to generate prelimi-
nary evidence that insufﬁcient muscle repair processes (blunted GH)
and impaired anti-inﬂammatory mechanisms (blunted cortisol, IL-10
and IL-1RA) in FMpatients result in an exaggerated pro-inﬂammatory cy-
tokine response (elevated IL-1β, TNF-α, IL-6, and IL-8) to unaccustomed
exercise and consequently a worsening of muscle pain, stiffness and
fatigue in the days post-exercise. Consistent with prior exercise inter-
ventions we found that in contrast to HCs, thighmuscle pain and tender-
ness increased in the FM group following exercise. FM participants also3.0
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Fig. 3. Post-exertional pain, tenderness, fatigue and stiffness. A) Post-exertional changes in loc
(PPT) before exercise (pre) and then 2-days (Day 2) and 4-days after exercise (Day 4) in FM
two (FM vs. HC) × 3 (pre-, Day 2, and Day 4) repeated measure ANOVA was used to analyze d
change in fatigue, and stiffness calculated from pre- and post-exercise FIQR/SIQR scores in FM
The asterisk represents a p b .05.experienced increased fatigue and stiffness post-exertion. Thus, our ﬁnd-
ings are consistent with FM patients beingmore prone to post-exertional
pain and tenderness than HCs. Although we hypothesized that insufﬁ-
cient muscle repair processes may contribute to the post-exertional
symptom exacerbation observed in FM patients, our preliminary ﬁndings
failed to support this idea.We foundnodifference in the exercise-induced
GH response between FM and HC participants. Our data conﬂict with
prior studies that showed a blunted GH response to exhaustive treadmill
exercise in women with FM using the same modiﬁed Balke protocol
(Jones et al., 2002, 2007; Paiva et al., 2002). This discrepancymay be relat-
ed to the smaller sample size used in the present study or the close
matching of FM and HCs on factors that inﬂuence the GH response to ex-
ercise. In addition to GH, serum levels of IL-6, IL-10, ACTH, and cortisol
also increased during exercise in HCs, and in general peaked at VO2
peak, before decreasing to pre-exercise levels an hour later. In contrast,
serum levels of pro-inﬂammatory TNF-α and IL-8 decreased during exer-
cise inHCs. Theseﬁndings support the idea that exercise stimulates a neu-
roendocrine and anti-inﬂammatory cytokine response that decreases
systemic inﬂammation in healthy individuals (Walsh et al., 2011). We
found that the exercise-induced anti-inﬂammatory cascade was blunted
in women with FM. Speciﬁcally, the ACTH, cortisol, and IL-10 responses
to exercise were blunted in FM patients relative to HCs. Aberrant ACTH
and cortisol secretion in response to various stressors have previously
been documented in people with FM (Adler et al., 1999; Paiva et al.,
2002; Kadetoff and Kosek, 2010; Bote et al., 2012). To our knowledge
this is the ﬁrst study to demonstrate a blunted exercise-induced IL-10 re-
sponse in women with FM. The failure to mount the expected cortisol,
and IL-10 response in FMs, both potent anti-inﬂammatory molecules
may explain why TNF-α levels declined in HCs during exercise but not
in FM participants. IL-6 infusion in healthy adults increases circulating
levels of cortisol and IL-10 (Steensberg et al., 2003). Yet, the blunted IL-
10 and cortisol response observed in FM participants in the present
study did not appear to be related to a similarly blunted IL-6 response
to exercise. IL-6 increased in both groups during exercise and then de-
creased toward baseline levels post-exercise. In the FM group, however,
IL-6 levels did not fall as rapidly as in HCs in the hour post-exercise. A de-
fect in IL-6 signaling rather than IL-6 secretion in FMmay explain why in
the context of a “normal” IL-6 response to exercise, downstream effectors
of IL-6 were not optimally induced (Sarvas et al., 2013).
Despite the blunted anti-inﬂammatory response observed in FM
participants during and immediately after the exercise test, there were
no group differences in IL-6, IL-10, and TNF-α at 2- and 4-days post-
exercise. In contrast, whereas IL-8 levels remained relatively constant
in HCs in the days following exercise they decreased sharply in FM par-
ticipants. The signiﬁcance of the decline in serum IL-8 in FM relative to
HCs is not clear. IL-8 is a chemokine that plays an important role in the-1.0
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blood levels of IL-8 have been reported in FMand are associatedwith in-
creased pain (Bazzichi et al., 2007; Ross et al., 2010; Ang et al., 2011;
Bote et al., 2012, 2013). While engagement in low intensity exercise
for several months has proven effective at reducing circulating IL-8
levels in FM and decreasing symptoms (Bote et al., 2013), the acute IL-
8 response to moderate to high intensity exercise has not been exam-
ined. We found no evidence that the increased post-exertional muscle
pain and tenderness, stiffness, and fatigue were mediated by changes
in circulating inﬂammatory cytokines either during exercise or in the
following days. This ﬁnding does not necessarily rule out an inﬂamma-
tory process in the exacerbation of these symptoms. The mediation
analysis was likely underpowered in our study due to small sample
size, decreasing our ability to detect these effects even if theywere pres-
ent. In addition, IL-1β and TNF-α act in a paracrine and autocrine man-
ner and circulating levels of these cytokines may not necessarily reﬂect
their activity in tissues i.e. damaged skeletal muscle. Indeed, the activa-
tion of immune cells following muscle damaging exercise, as evidenced
by increased myoglobin levels, can occur without appreciable changes
in circulating inﬂammatorymarkers (Kanda et al., 2013).Measuring im-
mune cell activation and their intracellular cytokine levels may be a
more sensitive and practical approach to assessing exercise-induced im-
mune changes in this population.
This study has several limitations that should be addressed in fu-
ture studies. First, FM participants were compared to HCs and not to
women with other non-FM pain disorders. Thus, it is possible that
group differences in the neuroendocrine and inﬂammatory re-
sponses to exercise observed in the present study are not speciﬁc
to FM. Although Wingenfeld et al. showed neuroendocrine dysfunc-
tion in women with FM but not in women with chronic pelvic pain
(Wingenfeld et al., 2008), inclusion of a more appropriate control
group is warranted in future exercise studies. Second, estradiol
levels were not measured in the present study. Estradiol, the prima-
ry biologically active estrogen, has anti-inﬂammatory effects in
humans (Puder et al., 2001). Although we found no group difference
in estrogen status, based on self-reported last menstrual period and
HRT usage, we acknowledge that a variation in estradiol levels could
still occur and may have inﬂuenced the serum neuroendocrine and
cytokine responses to exercise. The assessment of estradiol levels
will be critical in follow-up studies. Finally, our sample size was rel-
atively small and future studies are needed with a larger sample size
to verify our ﬁndings.
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